Evidence map›Paper›PMID 27825120›Full record

ArticleOncotarget2016

Trans-ethnic follow-up of breast cancer GWAS hits using the preferential linkage disequilibrium approach.

Qianqian Zhu, Lori Shepherd, Kathryn L Lunetta, Song Yao, Qian Liu, Qiang Hu, Stephen A Haddad, Lara Sucheston-Campbell, Jeannette T Bensen, Elisa V Bandera and 6 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Atypical Chemokine Receptor 1 (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Qianqian ZhuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lori ShepherdDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kathryn L LunettaDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Qian LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Qiang HuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Stephen A HaddadSlone Epidemiology Center, Boston University, Boston, MA, USA.
Lara Sucheston-CampbellDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Jeannette T BensenDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Elisa V BanderaCancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Lynn RosenbergSlone Epidemiology Center, Boston University, Boston, MA, USA.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Andrew F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, MA, USA.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USBoston University · USUniversity of North Carolina at Chapel Hill · USRutgers, The State University of New Jersey · USUniversity of Southern California · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
FOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Understanding Ethnic Differences in Cancer: The Multiethnic Cohort StudyUM1CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HENDERSON, BRIAN E, LE MARCHAND, LOIC · 2012 to 2014
$11.3M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Obesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2M
Gene Polymorphisms in Relation to Cancer in Black WomenR01CA098663 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PALMER, JULIE R · 2003 to 2012
$5.3M
Race &Risk Factors for Early/Aggressive Breast CancerR01CA100598 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2004 to 2008
$4.8M
NCI NIH HHS P01 CA151135NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA058420NCI NIH HHS R01 CA098663NCI NIH HHS R01 CA100598NCI NIH HHS R01 CA185623NCI NIH HHS U01 CA179715NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA164974NICHD NIH HHS P2C HD050924NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

Leveraging population-distinct linkage equilibrium (LD) patterns, trans-ethnic follow-up of variants discovered from genome-wide association studies (GWAS) has proved to be useful in facilitating the identification of bona fide causal variants. We previously developed the preferential LD approach, a novel method that successfully identified causal variants driving the GWAS signals within European-descent populations even when the causal variants were only weakly linked with the GWAS-discovered variants. To evaluate the performance of our approach in a trans-ethnic setting, we applied it to follow up breast cancer GWAS hits identified mostly from populations of European ancestry in African Americans (AA). We evaluated 74 breast cancer GWAS variants in 8,315 AA women from the African American Breast Cancer Epidemiology and Risk (AMBER) consortium. Only 27% of them were associated with breast cancer risk at significance level α=0.05, suggesting race-specificity of the identified breast cancer risk loci. We followed up on those replicated GWAS hits in the AMBER consortium utilizing the preferential LD approach, to search for causal variants or better breast cancer markers from the 1000 Genomes variant catalog. Our approach identified stronger breast cancer markers for 80% of the GWAS hits with at least nominal breast cancer association, and in 81% of these cases, the marker identified was among the top 10 of all 1000 Genomes variants in the corresponding locus. The results support trans-ethnic application of the preferential LD approach in search for candidate causal variants, and may have implications for future genetic research of breast cancer in AA women.

Indexed as

Linkage DisequilibriumPolymorphism, Single NucleotideAgedBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCase-Control StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMiddle AgedPhenotypeRegistriesRisk AssessmentBiomarkers, Tumorcausal variantfine-mappinggenome-wide association studies

Identifiers

PMID27825120
PMCPMC5341253
OpenAlexW2548108432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.